Dr. Frigault is a medical oncologist in the Hematologic Malignancy Program at the Massachusetts General Hospital Cancer Center, as well as Assistant Director of the Cellular Therapy Service. In addition, he serves as an Instructor at Harvard Medical School. Dr. Frigault recently completed his oncology fellowship at the combined Massachusetts General Hospital/Dana Farber Cancer Institute training program where he worked with Dr. Marcela Maus, head of the Cellular Immunotherapy Program at Massachusetts General Hospital.

Dr. Frigault is responsible for attending on the inpatient bone marrow transplant and leukemia services, managing outpatient cellular therapy patients and overseeing the cellular therapy service in charge of the hospital’s standard of care and clinical research efforts. His current research is focused on the translational aspects of cellular therapies with the goal of developing the next generation of cellular therapies utilizing multi-cistronic lentiviral vectors, CRISPR gene editing and clinical correlatives.

Dr. Frigault’s prior research experience includes preclinical development and correlative studies relevant to T cell immunotherapy in the lab of Dr. Carl June while in graduate school at the University of Pennsylvania. During his post-graduate training at Johns Hopkins, he focused on cellular therapies utilizing marrow infiltrating lymphocytes and chimeric switch receptors in the lab of Dr. Ivan Borrelo.

Dr. Frigault received his Bachelor of Arts degree in Biology and Biological Sciences from the College of the Holy Cross, and his master’s and M.D. degrees from the University of Pennsylvania.

Since 1997, Dr. Alexander Gabibov has been Head of the Laboratory of Biocatalysis at the Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry at the RAS, and in 2000 he became Professor of Cell Biology at the Moscow State University. In 2003, Dr. Gabibov was named an Associate of the Russian Academy of Sciences, and in 2008 was appointed President of the Russian Biochemical and Molecular Biology Society.

In 2009, Dr. Gabibov took on the role of Foreign Correspondent at the National Academy of Pharmacy in France. In 2012, he was nominated as Head of Department of Industrial Pharmacology at the Lomonosov Moscow State University. 

Throughout his career, Dr. Gabibov has been a prolific contributor to the global scientific community as both a frequent contributor to learned journals as well - and especially in the last six years - as a much sought-after speaker on the international conference circuit.

Dr. Gabibov graduated from Moscow State University in 1977, where he studied Chemical Enzymology. He currently holds several senior positions in the Biochemistry sphere in both Russia and France.

Dr. Guenther Koehne is an internationally recognized cancer specialist and current Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at the Miami Cancer Institute. He has over 30 years of extensive experience in the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, including with autologous and allogeneic stem cell transplantations. Over the course of his career, he has established a noteworthy reputation for his work in adoptive immunotherapeutic approaches with antigen-specific, donor-derived T lymphocytes in the treatment of viral complications following allogeneic transplants and has developed new approaches to the treatment of patients with high-risk multiple myeloma, minimal residual disease of leukemia and relapsed disease post-allogeneic bone marrow transplantation.

Prior to joining the Miami Cancer Institute, Dr. Koehne served as both the Assistant Professor of Medicine and Associate Professor of Medicine at Weill Cornell Medicine. Prior to that, Dr. Koehne spent over 20 years at the Memorial Sloan Kettering Cancer Center (MSKCC) and held a multitude of roles, including Medical Director of the Cytotherapy Laboratory (Bone Marrow Transplantation Laboratory) and Hematologic Oncologist. While serving as the Medical Director at MSKCC, he established new T cell depletion techniques and other methods to manipulate donor stem cell products that optimize patient outcomes.

Dr. Koehne has served as Principle Investigator or Principal Co-Investigator for a number of clinical trials involving bone marrow transplantation, particularly in the area of multiple myeloma, to study the effectiveness of T cell-depleted transplants from related and unrelated donors in patients with high-risk and relapsed multiple myeloma. He is regarded in the medical community as a pioneer in developing specific donor-derived immune cells (T lymphocytes) to treat both the viral complications of transplantation and disease relapse following transplantation. His developed treatment approach is a type of adoptive immunotherapy and is being administered in several active clinical trials.

A physician-scientist, Dr. Koehne received his M.D. and Ph.D. from Medical University of Hamburg, Germany. He completed his residency in Internal Medicine at Medical University of Hamburg and Rush University Medical Center in Chicago. He completed his medical oncology/hematology fellowship at Memorial Sloan Kettering Cancer Center, and an additional research fellowship in the Immunology Program at the Sloan Kettering Institute for Cancer Research, Allogeneic Bone Marrow Transplantation Service, where he also served as a research associate.

Since 2010, Greg MacMichael, Ph.D., has served as the President and Founder of CMC BioServices, LLC, a well-established consulting firm through which he has assisted innovators and biopharmaceutical companies with successful development and licensure of cell and gene therapies, biologics and vaccines. Dr. MacMichael most recently served as the Senior Vice President of Technical Operations at Axovant Gene Therapies where he oversaw the manufacturing of Axovant's pipeline of gene therapies. Over the course of his 35 years of experience in biopharmaceuticals, Dr. MacMichael held positions such as Senior Vice President of Development, Manufacturing and Quality Control at NantKwest Therapeutics and Senior Vice President of Process, Development, Manufacturing and Quality Assurance at Rocket Pharma. Additionally, he previously served as the Global Head of Biologics Process Development at Novartis, where he led the CMC aspects of Novartis' acquisition and transfer of Kymriah® from the University of Pennsylvania, including building the supply chain for plasmids, lentiviral vector and production capacity.

Dr. MacMichael received his Ph.D. in microbiology/biochemistry from Mississippi State University, his M.S. in microbiology/biochemistry from North Carolina State University and his B.S. in microbiology from Pennsylvania State University.

Dr. Mamonkin is a leading research expert in developing new therapeutic tools to treat hematologic malignancies and solid tumors using adoptive cell therapy. He currently serves as an Assistant Professor in the Center for Cell and Gene Therapy and maintains academic appointment in the Department of Pathology and Immunology at Baylor College of Medicine in Houston, Texas. Dr. Mamonkin directs a laboratory that focuses on investigating the mechanisms and effects of CAR signaling in therapeutic T cells and developing new engineered approaches using genome editing and synthetic biology to enhance cell therapy of aggressive hematologic malignancies. He oversees clinical translation of investigational therapies though cGMP manufacturing to the clinic and serves as a co-principal investigator on several ongoing and upcoming clinical trials of CAR T cells in hematologic malignancies at Baylor College of Medicine.

Dr. Mamonkin received his Ph.D. in Immunology at Baylor College of Medicine studying the transcriptional regulation of T-cell differentiation in response to bacterial infection and completed his postdoctoral training with Dr. Malcolm Brenner at the Center for Cell and Gene Therapy, Baylor College of Medicine.

Dr. Stepanov is a leading research expert in developing personalized therapeutic tools for lymphoproliferative diseases using immunotoxins or adoptive cell therapy. He currently serves as a Senior Staff Scientist in the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry. At the same time, Dr. Stepanov maintains a Senior Staff Scientist position in the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology in Russia. Dr. Stepanov directs a group in the laboratory of biocatalysis at the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry that focuses on developing novel approaches for safe and controlled adoptive immunotherapy by CAR T cells. Dr. Stepanov is a professional scientific collaborator of Dr. Richard Lerner's laboratory in Scripps Research.

Dr. Xie is a prominent researcher at Scripps Research responsible for inventing a collection of new technologies for antibody drug discovery and cell therapy. He has been working at Scripps Research since 2011 and currently serves as a Senior Scientist at the Department of Chemistry. He is specialized in new platform development and therapeutic molecule discovery. In the past, Dr. Xie and his team have invented a collection of new technologies for antibody drug discovery and cell therapy, which were licensed by biotech companies and led to joint collaboration efforts with large pharmaceutical companies.